Purpose. To characterize the economic and quality of life burden of diabetic macular edema (DME) in Canadian patients. Patients and Methods. 145 patients with DME were followed for 6 months with monthly telephone interviews and medical chart reviews at months 0, 3, and 6. Visual acuity in the worst-seeing eye was assessed at months 0 and 6. DME-related healthcare costs were determined over 6 months, and vision-related (National Eye Institute Visual Functioning Questionnaire) and generic (EQ-5D) quality of life was assessed at months 0, 3, and 6. Results. Mean age of patients was 63.7 years: 52% were male and 72% had bilateral DME. At baseline, visual acuity was categorized as normal/mild loss for 63.4% of patients, moderate loss for 10.4%, and severe loss/nearly blind for 26.2%. Mean 6-month DME-related costs/patient were as follows: all patients (n = 135), $2,092; normal/mild loss (n = 88), $1,776; moderate loss (n = 13), $1,845; and severe loss/nearly blind (n = 34), $3,007. Composite scores for vision-related quality of life declined with increasing visual acuity loss; generic quality of life scores were highest for moderate loss and lowest for severe loss/nearly blind. Conclusions. DME-related costs in the Canadian healthcare system are substantial. Costs increased and vision-related quality of life declined with increasing visual acuity severity.
OBJECTIVES:To characterize the economic and societal burden of Diabetic Macular Edema (DME) in Canada. METHODS: Patients with clinically significant macular edema (CSME) were enrolled by ophthalmologists or retinal specialists across Canada. Patients are followed over a 6-month period to combine prospective data collected during monthly telephone interviews and at sites at months 0, 3 and 6. Visual acuity (VA) is measured and DME-related health care resource information is collected. Patient health-related quality of life is measured using the National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25), and the EuroQol Five Dimensions (EQ-5D). The 3-month results are available and presented here. RESULTS: A total of 145 patients [mean age 63.8 years (range: 30-86 yrs); 52% male; 81% Type 2 diabetes; mean duration of diabetes 18 years (range: 1-62 yrs); 72% bilateral CSME] were enrolled from 17 sites across 6 provinces in Canada. At baseline, the mean VA was 20/60 (range: 20/20-20/800) across all eyes diagnosed with CSME (249 eyes). Sixty-eight percent of patients had VA severity in the worse seeing eye of normal/mild vision loss (VA 20/10 to Յ 20/80), 19% moderate vision loss (VA Ͼ 20/80 to Յ 20/200), and 13% severe vision loss/nearly blind (VA Ͼ 20/200). At month 3, the mean NEI VFQ-25 composite score was 79.9, the mean EQ-5D utility score was 0.79, and the EQ visual analogue scale score was 70.6. The average
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.